AcquisitionsAug 3, 2026, 02:21 PM
AbbVie to Acquire Apogee Therapeutics for $10.9B; Q2 Net Earnings Up 285%
AI Summary
AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, expanding its pipeline in inflammatory conditions. This strategic move accompanies strong second-quarter financial results, with net revenues increasing by 10.2% to $16.99 billion and net earnings attributable to AbbVie Inc. soaring by 285.2% to $3.61 billion. The company also reported significant licensing activities and robust operating cash flow for the first half of 2026.
Key Highlights
- AbbVie to acquire Apogee Therapeutics for approximately $10.9 billion.
- Q2 2026 net revenues increased 10.2% to $16.99 billion.
- Q2 2026 net earnings attributable to AbbVie Inc. rose 285.2% to $3.61 billion.
- Q2 2026 diluted EPS increased 290.4% to $2.03.
- Six months ended June 30, 2026, operating cash flow was $7.27 billion.
- Entered license agreement with RemeGen with $650 million upfront payment.
- Paid $6.16 billion in dividends and repurchased $1.50 billion in stock in H1 2026.
Price Impact
More from ABBV